[{"orgOrder":0,"company":"Kare Biosciences","sponsor":"JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ramatroban","moa":"Thromboxane A2 receptor | G protein-coupled receptor 44","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kare Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kare Biosciences \/ JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences","highestDevelopmentStatusID":"9","companyTruncated":"Kare Biosciences \/ JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences"},{"orgOrder":0,"company":"Biolink LifeSciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Ramatroban","moa":"Thromboxane A2 receptor | G protein-coupled receptor 44","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biolink LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolink LifeSciences \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"Biolink LifeSciences \/ BARDA"}]

Find Clinical Drug Pipeline Developments & Deals for Ramatroban

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Lead Product(s) : Ramatroban

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase II/ Phase III

                          Sponsor : JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Ramatroban is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 31, 2023

                          Lead Product(s) : Ramatroban

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : Ramatroban (KARE 101), a dual blocker of thromboxane and prostanoid receptors, has demonstrated efficacy in animal models of respiratory dysfunction, atherosclerosis, thrombosis, and sepsis, and evidence for rapid relief of dyspnea and hypoxemia in COVID...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 05, 2022

                          Lead Product(s) : Ramatroban

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : BARDA

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank